Skip to main content
Premium Trial:

Request an Annual Quote

Biodiversity to Develop Post-transplant Dx on BD Max System

NEW YORK (GenomeWeb News) – BD Diagnostics said today that Italian biotech and molecular diagnostics company Biodiversity will develop and commercialize tests tailored for BD's platform for the detection of infections in transplant patients, as part of a regional collaboration.

Biodiversity will develop a portfolio of molecular assays to run on the BD Max System's open architecture. The assays will be for patients who have undergone transplants.

Following a transplant, patients are often given drugs to suppress their immune systems to prevent rejection. This, however, puts a patient at higher risk for infection.

"Early and accurate diagnosis of infection is often essential to monitor and protect patient health following a transplant procedure," BD said, and the assays being developed under today's collaboration can expand the testing capabilities for molecular laboratories, which, in turn, can lead to faster testing results and earlier diagnosis for transplant patients.

The assays are planned for CE marking for sale and distribution in Europe. Commercialization of the assays in additional regions is expected to follow.

“This [testing technology] will empower laboratories with a new choice to improve the efficiency, accuracy, and speed to diagnose these types of infections," Tom Polen, President of BD Diagnostics – Diagnostic Systems, said in a statement.

BD Diagnostics is a segment of Becton Dickinson.

Financial and other terms of the deal were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.